COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

Protocol No
JANSSEN-64407564MMY1002
Principal Investigator
Anita D'Souza
Phase
I
Summary
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death. JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death. Daratumumab is a human monoclonal antibody or protein drug. An antibody is something that finds and kills foreign cells and organisms in your body, in this case, myeloma cells.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL